Vaccine News and Research

Latest Vaccine News and Research

Scientists target protein-detection approach to systematically measure human repertoire of proteins

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

9 Dec 2013

Imported measles poses a threat to health security

Experts report that measles still poses a threat to public health in the U.S, despite vaccination having successfully eliminated the endemic since the 1960s.

6 Dec 2013

Edison Investment Research's report examines long-term investment case for Bavarian Nordic

Edison Investment Research's report, An intriguing PROSPECT, examines the long-term investment case for Bavarian Nordic, which rests on key value driver Prostvac, its Phase III prostate cancer vaccine.

6 Dec 2013

Longer reads: HIV secrets, millennials' mental health and sleeping pills without side effects

Every week reporter Ankita Rao selects interesting reading from around the Web.

6 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

Measles still poses threat to domestic and global health security

Fifty years after the approval of an extremely effective vaccine against measles, one of the world's most contagious diseases, the virus still poses a threat to domestic and global health security.

5 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

"Virtual T cell" predicts how human immune system reacts to foreign substances

A platform that simulates how the body defends itself: The T cells of the immune system decide whether to trigger an immune response against foreign substances.

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

VTT receives innovation prize for technological development work behind allergy vaccine

The European Association of Research and Technology Organisations EARTO has awarded VTT Technical Research Centre of Finland an innovation prize for the technological development work behind allergy vaccine.

5 Dec 2013

Viewpoints: Why can't health website be like Amazon?; debunking GOP's resistance to Medicaid

For an "Amazon-like" experience, it isn't enough to have a website that functions on the front end, the back end and in between. ... You also need an Amazon-like culture, which is the product of other Amazon-like realities.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

TB vaccine may help prevent multiple sclerosis

A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

Wrapping in low molecular weight poly can help stabilize hemoglobin

A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, a discovery that could lead to the development of stable vaccines and affordable artificial blood substitutes.

4 Dec 2013

1950s H2N2 avian influenza A virus still pose threat to human health

St. Jude Children's Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology.

4 Dec 2013

UCI-led study results have important implications for HIV vaccine development

Infectious disease researchers have identified a novel mechanism wherein HIV-1 may facilitate its own transmission by usurping the antibody response directed against itself. These results have important implications for HIV vaccine development and for understanding the earliest events in HIV transmission.

4 Dec 2013

Better understanding of cancer evolution could help in early detection of cancers

A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.

4 Dec 2013

Vaccine News and Research

Latest Vaccine News and Research

Scientists target protein-detection approach to systematically measure human repertoire of proteins

Imported measles poses a threat to health security

Edison Investment Research's report examines long-term investment case for Bavarian Nordic

Longer reads: HIV secrets, millennials' mental health and sleeping pills without side effects

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Measles still poses threat to domestic and global health security

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

"Virtual T cell" predicts how human immune system reacts to foreign substances

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

IDSA released new guideline for vaccination of immunocompromised hosts

VTT receives innovation prize for technological development work behind allergy vaccine

Viewpoints: Why can't health website be like Amazon?; debunking GOP's resistance to Medicaid

New method for counting tumor-fighting cells to predict ovarian cancer

TB vaccine may help prevent multiple sclerosis

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

Wrapping in low molecular weight poly can help stabilize hemoglobin

1950s H2N2 avian influenza A virus still pose threat to human health

UCI-led study results have important implications for HIV vaccine development

Better understanding of cancer evolution could help in early detection of cancers

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in